LDLR and familial hyperaldosteronism: With regards to LDL clearance, studies of humans (including those with familial hypercholesterolemia (FH)) receiving evinacumab have yielded similar results, demonstrating LDL lowering independently of LDLR (12, 30, 31, 35, 36).